← All stories
Markets
Diaceutics (DXRX) Partners with Precision Cancer Consortium to Launch NGS Concordance Study Enhancing Biomarker Testing in Oncology
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider for the pharmaceutical and biotech sectors, has announced the initiation of an NGS Concordance Study in collaboration with the Precision Cancer Consortium (PCC). This j…
Covered by 1 outlet
All coverage · 1 article